Morgan Stanley Hikes McKesson (MCK) Price Target on Earnings Growth Prospects

Abdul Rahman

Tue, Jun 17, 2025, 1:24 AM 1 min read

McKesson Corporation (NYSE:MCK) is one of the 12 best healthcare stocks to buy now. On June 11, Morgan Stanley reiterated the stock’s ‘Overweight’ rating and increased the price target to $770 from $745. The adjustment follows a discussion with the executive team that left the research firm optimistic about the company’s growth prospects.

A doctor inspecting a medical device made by the medical device company.

According to Morgan Stanley, McKesson is benefiting from enhanced operational performance. Consequently, it remains confident that the company will achieve its fiscal year 2026 earnings per share forecast of $37.31. The bullish outlook underscores the expected improvement in adjusted operating income across various segments.

McKesson Corporation (NYSE:MCK) is a global healthcare company that operates through four main business segments: US Pharmaceutical, Rx Technology Solutions, Medical-Surgical Solutions, and Global Operations. It provides healthcare information technology, medical supplies, and health management tools.

While we acknowledge the potential of MCK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10.

Disclosure: None.